Results 11 to 20 of about 19,829 (313)
Camelid immunoglobulins and nanobody technology [PDF]
Veterinary Immunology and Immunopathology, 2008 It is well established that all camelids have unique antibodies circulating in their blood. Unlike antibodies from other species, these special antibodies are devoid of light chains and are composed of a heavy-chain homodimer. These so-called heavy-chain antibodies (HCAbs) are expressed after a V-D-J rearrangement and require dedicated constant gamma ...
Serge Muyldermans +16 more
openalex +7 more sources
Structure of Nanobody Nb23 [PDF]
Molecules, 2021 Background: Nanobodies, or VHHs, are derived from heavy chain-only antibodies (hcAbs) found in camelids. They overcome some of the inherent limitations of monoclonal antibodies (mAbs) and derivatives thereof, due to their smaller molecular size and higher stability, and thus present an alternative to mAbs for therapeutic use.
Percipalle M. +4 more
openaire +6 more sources
Immunogenicity Risk Profile of Nanobodies [PDF]
Frontiers in Immunology, 2021 Nanobodies (Nbs), the variable domains of camelid heavy chain-only antibodies, are a promising class of therapeutics or in vivo imaging reagents entering the clinic. They possess unique characteristics, including a minimal size, providing fast pharmacokinetics, high-target specificity, and an affinity in the (sub-)nanomolar range in conjunction with an
Chloé Ackaert +17 more
openaire +5 more sources
Seminars in Immunology, 2021 For treatment and diagnosis of cancer, antibodies have proven their value and now serve as a first line of therapy for certain cancers. A unique class of antibody fragments called nanobodies, derived from camelid heavy chain-only antibodies, are gaining increasing acceptance as diagnostic tools and are considered also as building blocks for chimeric ...
Andrew W. Woodham +3 more
openaire +4 more sources
Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics [PDF]
Frontiers in Immunology, 2017 Monoclonal antibodies have revolutionized cancer therapy. However, delivery to tumor cells in vivo is hampered by the large size (150 kDa) of conventional antibodies. The minimal target recognition module of a conventional antibody is composed of two non-covalently associated variable domains (VH and VL).
Peter Bannas +2 more
openalex +5 more sources
Antibodies, 2020 Since their first description in 1993 [...]
Patrick Chames, Ulrich Rothbauer
openaire +5 more sources
Journal of Hematology & Oncology, 2023 Background T cell engagers (TCEs) have been established as an emerging modality for hematologic malignancies, but solid tumors remain refractory. However, the upregulation of programmed cell death 1 (PD-1) is correlated with T cell dysfunction that ...
Ziqiang Ding +12 more
doaj +1 more source
Recent advances of nanobody applications in diagnosis and detection
MedComm – Biomaterials and Applications, 2023 Nanobodies (Nbs) are the variable domain of heavy‐chain antibodies derived from the blood of camelids or sharks. Nanobodies are the smallest antibody fragment with intact antigen‐binding ability.
Qianling Su +5 more
doaj +1 more source
The Application of Nanobody in CAR-T Therapy [PDF]
Biomolecules, 2021 Chimeric antigen receptor (CAR) T therapy represents a form of immune cellular therapy with clinical efficacy and a specific target. A typical chimeric antigen receptor (CAR) construct consists of an antigen binding domain, a transmembrane domain, and a cytoplasmic domain.
Lin-Lin Li +10 more
openaire +3 more sources
Chemogenetic Control of Nanobodies [PDF]
Nature Methods, 2019 ABSTRACTWe introduce an engineered nanobody whose affinity to green fluorescent protein (GFP) can be switched on and off with small molecules. By controlling the cellular localization of GFP fusion proteins, the engineered nanobody allows to study their role in basic biological processes, an approach that should be applicable to numerous previously ...
Shotaro Otsuka +12 more
openaire +6 more sources